Weill Cornell Medicine cancer researchers uncover protein released in exosomes secreted by melanoma cells that leads to lymphangiogenesis.

Columbia neuro-oncologist leads international phase 2 trial of selinexor, the first of a new class of anticancer drugs.

Oncologists and other specialists at NewYork-Presbyterian Hospital continue to contribute their expertise and resources to scientific investigations of COVID-19 and its implications for oncology care.

Research by Adam Mor, MD, PhD, a rheumatologist and molecular immunologist at NewYork-Presbyterian/Columbia University Irving Medical Center, focuses on the function of T lymphocytes in autoimmune disease and cancer

In the rapidly evolving field of cardio-oncology, NewYork-Presbyterian Hospital is making its mark with dedicated programs led by cardiology faculty at Columbia University Vagelos College of Physicians and Surgeons and Weill Cornell Medicine.

Comprehensive medical and surgical oncology programs for pancreatic cancer at NYP complement exhaustive research underway by Columbia and Weill Cornell faculty in the basic, translational, and clinical arenas. Their goal is to identify new treatment approaches that defy the odds for surviving this devastating disease.

Patients with Bacillus Calmette-Guerin (BCG)-unresponsive bladder cancer remain a challenging patient population to treat. Radical cystectomy continues as the oncologic gold standard treatment in patients at high risk of recurrence after BCG failure in non-muscle-invasive bladder cancer.

For more than two decades, Dr. Manuel Hidalgo has pursued laboratory and clinical research with a major focus on drug development in pancreatic cancer.